Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: A pilot study

Singh, Rajkumar Bikramjit; Chander, Subhash; Mohanti, BK; Pathy, Sushmita; Kumar, Sunesh; Bhatla, Neerja; Thulkar, Sanjay; Vishnubhatla, Sreenivas; Kumar, Lalit

doi:10.1016/j.ygyno.2013.01.011

Cited by 41 publications

(31 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Grade 3-4 hematologic toxicity was seen in about 20% of patients. These observations are encouraging [52,53] and need confirmation in a randomized study.…”

Section: Dose-dense Nact Prior To Ccrtmentioning

confidence: 66%

Integrating Chemotherapy in the Management of Cervical Cancer: A Critical Appraisal

Kumar

Gupta

2016

Oncology

Self Cite

View full text Add to dashboard Cite

The management of locally advanced cervix cancer has undergone a paradigm shift during the last decade. Concurrent chemoradiation (CCRT) (with cisplatin alone or in combination) is currently the standard treatment approach. CCRT results in a 5-year overall survival rate of 66% and a disease-free survival of 58%. About 30-40% of patients with locally advanced cervical cancer fail to achieve complete response to CCRT; alternative approaches are needed to improve the outcome for such patients. Weekly paclitaxel and carboplatin for 4-6 weeks as dose-dense chemotherapy prior to CCRT could be one such potential approach. The role of adjuvant chemotherapy after CCRT in patients with positive lymph nodes, larger tumor volume and stage III-IVA disease needs further exploration. Adjuvant chemotherapy is also being investigated for early-stage (stages IA2, IB1 or IIA) cervical cancer with presence of risk factors such as lymph node metastasis, lymphovascular space invasion and invasion depth of more than 10 mm, microscopic parametrial invasion, non-squamous histology and positive surgical margins. For patients with early-stage disease (IA2-IIA), short-course chemotherapy prior to surgery is associated with an improved outcome in many studies. Neo-adjuvant chemotherapy followed by fertility preservation surgery is feasible in carefully selected young patients with bulky stage IB1 disease. Recently, a number of molecular pathways have been identified as potential therapeutic targets. Bevacizumab - an inhibitor of vascular endothelial growth factor - is associated with improved survival in patients with recurrent/metastatic cervical cancer. Whether bevacizumab and other similar novel agents targeting molecular pathways could be used in front-line treatment along with cytotoxic chemotherapy is likely to be an area of research in future studies.

show abstract

“…Grade 3-4 hematologic toxicity was seen in about 20% of patients. These observations are encouraging [52,53] and need confirmation in a randomized study.…”

Section: Dose-dense Nact Prior To Ccrtmentioning

confidence: 66%

Integrating Chemotherapy in the Management of Cervical Cancer: A Critical Appraisal

Kumar

Gupta

2016

Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, our observed response rate after NACT (100% with 40% CR) and overall survival at 3 years (80%) were higher than that described by McCormack et al (70% and 68%, respectively). The 3 year data were not reported by Singh et al, where the median follow-up period was 22 months [27,28].…”

Section: Discussionmentioning

confidence: 84%

“…The question whether NACT or chemoradiation is a more effective treatment is the subject of investigation of the European Organization for Research in Cancer Therapy (EORTC) protocol 55994 (NCT00193739) and is expected to address the role of NACT and chemoradiation in this settings [26]. We compared our results with similar trials available in the literature which have used the chemoradiation approach [27,28]. These two trials have evaluated the dose-dense neoadjuvant chemotherapy (NACT) with paclitaxel and carboplatin before radical chemoradiation (CRT) in locally advanced cervical cancer.…”

Section: Discussionmentioning

confidence: 99%

Low-dose fractionated radiation and chemotherapy prior to definitive chemoradiation in locally advanced carcinoma of the uterine cervix: Results of a prospective phase II clinical trial

Das

John

Reddy

et al. 2015

Gynecologic Oncology

View full text Add to dashboard Cite

“…Neoadjuvant chemotherapy compliance was more than 90% in published trials. 11,12 The median (range) number of chemotherapy cycles was 4 (2Y6) in Graham's trial, 5 (1Y8) cycles in Paulson's trial, and 72% of patients received 4 or more cycles in Reed's trial. Rodriguez-Riao et al 13 reported 82.4% for NACT compliance and Nagai et al 14 reported full adherence to NACT.…”

Section: Resultsmentioning

confidence: 99%

Neoadjuvant Chemotherapy Followed by Chemoradiation in Cervical Carcinoma: A Review

Azevedo¹,

Thuler²,

Mello³

et al. 2016

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: A pilot study

Cited by 41 publications

References 12 publications

Integrating Chemotherapy in the Management of Cervical Cancer: A Critical Appraisal

Integrating Chemotherapy in the Management of Cervical Cancer: A Critical Appraisal

Low-dose fractionated radiation and chemotherapy prior to definitive chemoradiation in locally advanced carcinoma of the uterine cervix: Results of a prospective phase II clinical trial

Neoadjuvant Chemotherapy Followed by Chemoradiation in Cervical Carcinoma: A Review

Contact Info

Product

Resources

About